Pooled Study Data Indicate Benefits of Early Selexipag Initiation in PAH
A new analysis that reviewed data from 2 studies in patients with pulmonary arterial hypertension (PAH) has found a benefit to initiating selexipag therapy within 6 months of diagnosis. The study, published in ERJ Open Research, found reduced disease progression in newly diagnosed patients in the TRITON and GRIPHON clinical trials who were on active…